Multiple Myeloma, Phase II
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Volunteers
Health Professionals
What is the purpose of this trial?
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Claire Aurilio
- Elan Gorshein, DO, JD, MPH
- Erica Stevens, APRN
- Jessica Mazzarella, APRN
- Jose Morales-Marin
- Karishma Mehra, MBBS
- Kayla Martello
- Laura Sabourin
- Madeline Santiago
- Natalia Neparidze, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Sabrina Browning, MD
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Tara Anderson, PA
- Tarsheen Sethi, MD, MSc
- Terri Parker, MD
- Vidya Kesavan
- Last Updated01/06/2026
- Study HIC#2000038338